Total Funding
62
40
Total FundingPost-IPO Equity raised
Growth Score
-1 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
185788
Chimeric Therapeutics is a company developing ground-breaking CAR T cell therapies for solid tumors.
Alison Gartner: Project ManagerPast Role: BioScience Managers Limited, Investment Manager- Jennifer Chow: Chief Executive Officer & Managing Director
About the Company
Chimeric Therapeutics is a company developing ground-breaking CAR T cell therapies for solid tumors based on research at the City of Hope Cancer Centre in Los Angeles. The technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor targeting component of the CAR to reprogram T cells and is currently
undergoing Phase 1 clinical trials at City of Hope in glioblastoma.
